Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lisata Therapeutics Inc (LSTA)

Lisata Therapeutics Inc (LSTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,171
  • Shares Outstanding, K 8,821
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -19,990 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.09
  • Price/Sales 18.17
  • Price/Cash Flow N/A
  • Price/Book 1.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.51
  • Number of Estimates 1
  • High Estimate -0.51
  • Low Estimate -0.51
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +7.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.85 +14.63%
on 12/03/25
2.17 -2.27%
on 12/01/25
+0.16 (+8.20%)
since 11/21/25
3-Month
1.81 +17.17%
on 11/21/25
2.98 -28.84%
on 10/31/25
-0.17 (-7.39%)
since 09/22/25
52-Week
1.81 +17.17%
on 11/21/25
4.20 -49.51%
on 01/06/25
-0.59 (-21.75%)
since 12/20/24

Most Recent Stories

More News
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Data rich period continues to support certepetide’s broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug...

LSTA : 2.06 (unch)
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’

BASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

LSTA : 2.06 (unch)
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

LSTA : 2.06 (unch)
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

LSTA : 2.06 (unch)
Lisata Therapeutics Highlights Cancer Therapy Innovations

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Lisata Therapeutics...

LSTA : 2.06 (unch)
Lisata Therapeutics to Present at LD Micro Main Event XIX

Basking Ridge, New Jersey--(Newsfile Corp. - October 13, 2025) -  Lisata Therapeutics, Inc. (NASDAQ: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies...

LSTA : 2.06 (unch)
Lisata Therapeutics Signs License Agreement with Catalent

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

LSTA : 2.06 (unch)
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag ® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent’s preclinical...

LSTA : 2.06 (unch)
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions BASKING RIDGE, N.J., Sept. 29,...

LSTA : 2.06 (unch)
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BASKING RIDGE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

LSTA : 2.06 (unch)

Business Summary

Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The company's principal product candidate includes LSTA1. Lisata Therapeutics Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 2.11
2nd Resistance Point 2.09
1st Resistance Point 2.08
Last Price 2.06
1st Support Level 2.05
2nd Support Level 2.03
3rd Support Level 2.02

See More

52-Week High 4.20
Fibonacci 61.8% 3.29
Fibonacci 50% 3.00
Fibonacci 38.2% 2.72
Last Price 2.06
52-Week Low 1.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar